



Surmodics to Present at Upcoming Investor Conferences

March 15, 2018

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Mar. 15, 2018-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and *in vitro* diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will be attending two upcoming investor conferences in New York City.

On Tuesday, March 20, at 1:35 p.m. ET (12:35 p.m. CT), company management will make a presentation at the Oppenheimer 28th Annual Healthcare Conference.

On Tuesday, March 27, at 2:30 p.m. ET (1:30 p.m. CT), company management will make a presentation at the Needham Healthcare Conference.

Live audio webcasts of the presentations can be accessed by going to the investor relations portion of the Company's website at www.surmodics.com and clicking on the webcast icon. Webcasts will be archived on the Company's website for 90 days.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for *in vitro* diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the SEC.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20180315005284/en/>

Source: Surmodics, Inc.

Surmodics, Inc.

Andy LaFrence, 952-500-7000

ir@surmodics.com